Drug giant Pfizer to pay record $2.3B fine STORY HIGHLIGHTS
The record $2.3 billion fine is for illegally promoting certain pharmaceuticals
One of those drugs was the anti-inflammatory medication linked to heart attacks
Company plead guilty for "misbranding . with the intent to defraud or mislead"
updated 7:17 p.m. EDT, Wed September 2, 2009 WASHINGTON (CNN) -- Pharmaceutical giant Pfizer has agreed to pay a record $2.3 billion settlement to
resolve criminal and civil liability for illegally promoting certain pharmaceuticals, the Justice Department
Pfizer pays record fine to avoid prosecution for illegally promoting certain drugs.
Officials from the Justice Department and the Department of Health and Human Services said the world's
largest drug company promoted four drugs for use on certain ailments or at dosages that were not approved
One of those drugs was the anti-inflammatory medication Bextra, which Pfizer pulled off the market in 2005
after it was linked to increasing the risk of heart attacks and strokes.
"Pfizer promoted the sale of Bextra for several uses and dosages that the FDA specifically declined to
approve due to safety concerns," the Justice Department said in a news release.
A Pfizer subsidiary, Pharmacia & Upjohn Company, agreed to plead guilty to a felony violation of the Food,
Drug and Cosmetic Act for "misbranding Bextra with the intent to defraud or mislead."
The settlement announcement said Pfizer also illegally promoted the anti-psychotic drug Geodon, the
antibiotic Zyvox and the anti-epilepsy drug Lyrica.
Associate Attorney General Tom Perrelli told reporters that recommending drugs for uses not approved by
the Food and Drug Administration creates a situation where "public health may be at risk."
"There can be a real danger for patients when medical providers are not provided with accurate and full
disclosure concerning a drug's risks and benefits," he said.
The Justice Department said Pfizer sales people created sham requests from physicians asking for
information about unapproved uses of certain drugs. The information was then mailed to doctors. Officials
said Pfizer also entertained doctors at resorts and encouraged them to prescribe its drugs.
The Justice Department also said the pharmaceutical giant provided kickbacks to health-care providers to
encourage them to prescribe other drugs, including Lipitor, Viagra and Zoloft.
Health and Human Services Secretary Kathleen Sebelius said the settlement is historic not only because of
the high financial penalty to Pfizer but also because the company will be subject to "the most comprehensive
corporate integrity agreement that a drug company has ever signed in the United States."
The terms call for Pfizer to conduct yearly audits and then certify it is in compliance with laws. They also
require the company to create a way for doctors to report questionable behavior by Pfizer sales people, and
say the company will post information on its Web site about payments and gifts to doctors.
Pfizer issued a statement saying, in part, "We regret certain actions taken in the past, but are proud of the
action we've taken to strengthen our internal controls."
The Justice Department said the investigation and settlement would not have been possible without the
assistance of whistle-blowers who worked at Pfizer. The settlement includes a provision for six of those
whistle-blowers to split more than $100 million dollars.
Stichwort-Chronik der BRK Bereitschaft Ebersdorf (Früher BRK Sanitätskolonne Ebersdorf-Frohnlach) 13.12.1931 Gründung der BRK Sanitätskolonne Ebersdorf-Frohnlach im Gasthaus „zum goldenen13.12.1931 1. Kolonnenführung: Kolonneführer Oscar Schilling, Stellvertreter Richard Welsch underster Kolonnenarzt Dr. Böckel aus Sonnefeld1937 Neuer Kolonneführer Richard Welsch aus Ebersdor
Acta Orthop. Belg. , 2006, 72 , 756-760 Doxycycline impairs tendon repair in rats Björn PASTERNAK, Mårten FELLENIUS, Per ASPENBERG From the Faculty of Health Sciences, Linköping University, Linköping, Sweden Doxycycline exhibits various effects apart from its MMPs are a group of zinc dependent neutral antimicrobial activity, such as inhibition of matrix proteinases that are cap